The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost

该公司领先的下一代单电池技术体系结构GEM-X能够以更大的规模和更低的成本实现更高的性能

PLEASANTON, Calif., March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3.

加利福尼亚州普莱森顿，2024年3月13日，单细胞和空间生物学领域的领导者，PRNewswire/-10x Genomics，Inc.（纳斯达克：TXG）今天宣布，它已经开始销售由GEM-X技术架构支持的前两种产品，铬单细胞基因表达3'v4和铬单细胞免疫分析5'v3。

GEM-X is the next generation of the company's leading single cell technology architecture and is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability..

GEM-X是该公司领先的单细胞技术体系结构的下一代，建立在新的和改进的微流控芯片设计之上，具有最新的技术进步和优化的试剂，具有优异的性能和高可靠性。。

'It's been incredible to see the enthusiasm from customers since we first announced the GEM-X architecture last month, and we can't wait to get these new products in researchers' hands,' said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer of 10x Genomics. 'GEM-X sets a new standard for single cell analysis and gives customers important performance advantages that will immediately benefit their research.

10x Genomics创始科学家兼首席技术官迈克尔·施纳尔·莱文（MichaelSchnallLevin）说：“自从上个月我们首次宣布GEM-X架构以来，看到客户的热情真是令人难以置信，我们迫不及待地想把这些新产品交给研究人员。”GEM-X为单细胞分析设定了新标准，并为客户提供了重要的性能优势，这将立即有益于他们的研究。

This is one of multiple steps we have planned to make single cell more accessible for all.'.

这是我们计划的多个步骤之一，以使所有人都能更容易地访问单个单元格。”。

GEM-X is exclusively available for use on Chromium X Series instruments and delivers important performance and workflow advantages, including:

GEM-X专门用于Chromium X系列仪器，具有重要的性能和工作流程优势，包括：

Substantially increased sensitivity: Detect up to two times more genes compared to on-market Chromium assays to gain a more comprehensive view of cellular heterogeneity

大大提高了灵敏度：与市场上的铬测定法相比，检测到的基因数量增加了两倍，以更全面地了解细胞异质性

Built to scale: Two-fold increase in cells captured per channel

按规模构建：每个通道捕获的细胞数量增加了两倍

More cost effective: More than two-fold reduction in cost per cell

更具成本效益：每个电池的成本降低了两倍以上

Enhanced data quality: Two-fold reduction in multiplet rate enabling high quality data at scale

提高了数据质量：多重集速率降低了两倍，从而实现了大规模的高质量数据

Maximum sample recovery: Recovery of up to 80% of cells, improving capture efficiency and making it ideal for samples typically yielding few cells, such as tissue biopsies or previously flow sorted cells

最大样品回收率：回收高达80%的细胞，提高捕获效率，使其成为通常产生少量细胞的样品的理想选择，例如组织活检或先前的流动分选细胞

Improved assay robustness: Redesigned microfluidics and optimized reagents for faster and more efficient cell partitioning

改进的测定稳健性：重新设计的微流体和优化的试剂可更快，更有效地进行细胞分配

'Selecting the optimal assay for single-cell experiments is challenging. However, it's evident that identifying more genes per cell enriches our understanding of cellular functions and the intricacies of biology,' said Luciano Martelotto, Associate Professor at the University of Adelaide. 'GEM-X, with its exceptional transcript capture, can enhance our capacity to differentiate cell types, spot rare cells and decode regulatory pathways.

“为单细胞实验选择最佳测定方法具有挑战性。然而，阿德莱德大学副教授卢西亚诺·马泰洛托（LucianoMartelotto）说，很明显，每个细胞识别更多的基因丰富了我们对细胞功能和生物学复杂性的理解GEM-X具有出色的转录本捕获功能，可以增强我们分化细胞类型，发现稀有细胞和解码调控途径的能力。

Improved accuracy in transcriptome data further facilitates the seamless integration of single-cell findings from diverse research projects and platforms.'.

转录组数据准确性的提高进一步促进了来自不同研究项目和平台的单细胞发现的无缝整合。”。

About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology.

约10x Genomics10x Genomics是一家生命科学技术公司，其产品旨在加速对生物学的掌握并促进人类健康。我们的综合解决方案包括用于单细胞和空间生物学的仪器，耗材和软件，可帮助学术和转化研究人员以及生物制药公司以与生物学复杂性相匹配的分辨率和规模了解生物系统。

Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter)..

我们的产品支持肿瘤学、免疫学、神经科学等领域的突破，推动了强有力的发现，改变了世界对健康和疾病的理解。要了解更多信息，请访问10xgenomics.com或通过LinkedIn或X（Twitter）与我们联系。。

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the 'safe harbor' provisions of those sections.

前瞻性声明本新闻稿包含《1933年证券法》第27A节（经修订）和《1934年证券交易法》第21E节（经修订）所载《1995年私人证券诉讼改革法》所指的前瞻性声明，这些条款属于这些条款的“安全港”条款。

All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

除历史事实陈述外，所有陈述都可能是前瞻性陈述。前瞻性陈述通常可以通过使用前瞻性术语来识别，例如“可能”、“可能”、“意志”、“应该”、“期望”、“计划”、“预期”、“可能”、“打算”、“目标”、“项目”、“设想”、“相信”、“估计”、“预测”、“潜在”或“继续”或其变体或类似术语，但是，没有这些词语并不意味着一项声明不具有前瞻性。

These forward-looking statements include statements regarding 10x Genomics, Inc.'s ('10x Genomics') product launches, performance, configuration, costs, capabilities, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors.

这些前瞻性声明包括有关10x Genomics，Inc.（“10x Genomics”）产品发布、性能、配置、成本、能力、采用和管道的声明。这些陈述基于管理层当前的期望、预测、信念、假设和管理层目前可获得的信息，由于多种因素，实际结果和结果可能与这些陈述存在重大差异。

Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the 'SEC') from t.

其他可能影响10x Genomics财务和运营结果并导致实际结果与本新闻稿中前瞻性声明所示结果产生重大差异的风险和不确定性包括在“风险因素”和“管理层对财务状况和运营结果的讨论和分析”标题下以及从t向美国证券交易委员会（“SEC”）提交10x基因组学文件。

Disclosure Information10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD..

披露信息10x Genomics使用向证券交易委员会、我们的网站（www.10xgenomics.com）、新闻稿、公共电话会议、公共网络广播和我们的社交媒体账户提交的文件，作为披露重大非公开信息的手段，并遵守FD法规规定的披露义务。。

ContactsInvestors: investors@10xgenomics.comMedia: media@10xgenomics.com

联系人投资者：investors@10xgenomics.comMedia时间：media@10xgenomics.com

SOURCE 10x Genomics, Inc

来源10x Genomics，Inc